IP Library › Granted Patent US 7,994,283
Granted Patent B2
US 7,994,283 · App. 12/455,444 · Granted Aug 9, 2011

Dimeric proteins for immunization

Assignee: Novartis Vaccines and Diagnostics SRL
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,994,283
App. No.
12/455,444
Granted
Aug 9, 2011
Kind
B2
Abstract

A dimeric protein comprising a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a targeting domain, a leucine zipper domain, and an antigen; and wherein the second fusion protein comprises a targeting domain, a leucine zipper domain, and optionally an antigen. Nucleic acid vectors encoding proteins of the invention are provided, particularly for use in nucleic acid vaccination.

Claims (29)

1. A dimeric protein comprising a first fusion protein and a second fusion protein,

wherein the first fusion protein comprises

(i) a targeting domain that comprises CTLA-4 or a fragment thereof,

(ii) a leucine zipper domain, and

(iii) an antigen;

and wherein the second fusion protein comprises:

(i) a targeting domain that comprises CTLA-4 or a fragment thereof,

(ii) a leucine zipper domain, and

(iii) optionally an antigen.

2. A dimeric protein according to claim 1 which is targeted to antigen presenting cells via the targeting domains.

3. A dimeric protein according to claim 1 or claim 2 where the targeting domains in the first and the second fusion proteins are the same.

4. A dimeric protein according to claim 1 or claim 2 where the targeting domains in the first and the second fusion proteins are different.

5. A dimeric protein according to claim 1 wherein the leucine zipper domains in the first fusion protein and the second fusion protein are the same.

6. A dimeric protein according to claim 1 wherein the leucine zipper domains in the first fusion protein and the second fusion protein are different.

7. A dimeric protein according to claim 5 wherein both leucine zipper domains are derived from the transcription factor GCN4.

8. A dimeric protein according to claim 6 wherein one leucine zipper domain is derived from the transcription factor fos and the other is derived from the transcription factor jun.

9. A dimeric protein according to claim 1 wherein the antigen in the first fusion protein and the antigen in the second fusion protein are the same.

10. A dimeric protein according to claim 1 wherein the antigen in the first fusion protein and the antigen in the second fusion protein are different.

11. A dimeric protein according to claim 1 wherein the second fusion protein does not comprise an antigen.

12. A fusion protein comprising:

(i) a targeting domain that comprises CTLA-4 or a fragment thereof

(ii) a leucine zipper domain and

(iii) an antigen.

13. A dimeric protein according to claim 1 , wherein the first fusion protein or the second fusion protein comprises a GCN4 leucine zipper domain.

14. A dimeric protein according to claim 1 , wherein the first fusion protein or the second fusion protein comprises a viral antigen.

15. A dimeric protein according to claim 1 , wherein the fragment comprises the CTLA-4 V-like domain.

16. A fusion protein according to claim 12 , wherein the fusion protein comprises a GCN4 leucine zipper domain.

17. A fusion protein according to claim 12 , wherein the fusion protein comprises a viral antigen.

18. A fusion protein according to claim 12 , wherein the fragment comprises the CTLA-4 V-like domain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2010
From: VALIANTE, NICHOLAS
To: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Reel/Frame 023733/0665 →
Priority Claims (1)
GB 0113798.3 · Jun 6, 2001 · national
Continuity (2)
Continuation 10479649
Related Publication 20100098718A1 · Apr 22, 2010